Biosyent Ownership

BIOYF Stock  USD 8.78  0.05  0.57%   
The market capitalization of Biosyent is $66.42 Million. Biosyent retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in world development indicators.

Biosyent Pink Sheet Ownership Analysis

About 41.0% of the company shares are held by company insiders. The book value of Biosyent was currently reported as 2.71. The company last dividend was issued on the 27th of February 2023. BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada. Biosyent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Biosyent is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on Biosyent please contact Ren Goehrum at 905 206 0013 or go to https://www.biosyent.com.

Biosyent Outstanding Bonds

Biosyent issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biosyent uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biosyent bonds can be classified according to their maturity, which is the date when Biosyent has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

Other Information on Investing in Biosyent Pink Sheet

Biosyent financial ratios help investors to determine whether Biosyent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biosyent with respect to the benefits of owning Biosyent security.